Mark Breidenbach

Mark Breidenbach

Analyst-Equity at Oppenheimer & Co., Inc. (Broker)

Consumer Services
Finance
Health Technology

Profile

Dr. Mark Breidenbach is Executive Director & Senior Analyst at Oppenheimer & Co., Inc. He covers Emerging Biotechnology.
Prior to joining the firm, Dr. Breidenbach worked at Roth Capital Partners as a lead Analyst covering Biotechnology and prior to that was a Managing Director and Senior Biotechnology Analyst at H.C.
Wainwright & Co. Prior to his Wall Street career, he was a Locum Scientist at Nature Publishing Group, and an Associate Specialist in Glycoproteomics and Metabolic Engineering at the Department of Chemistry, University of California Berkeley.
He holds a Ph.D.
in Molecular and Cellular Physiology from Stanford University, a M.
Phil.
from the Department of Molecular Biophysics and Biochemistry at Yale University, and a dual B.A.
in Biology and Chemistry from Cornell University.

Mark Breidenbach active positions

CompaniesPositionStart
Analyst-Equity 30/04/2017
All active positions of Mark Breidenbach

Former positions of Mark Breidenbach

CompaniesPositionEnd
Analyst-Equity 30/04/2017
Analyst-Equity 30/06/2016
Corporate Officer/Principal 27/02/2013
University of California, Berkeley Corporate Officer/Principal 30/10/2012
See the detail of Mark Breidenbach's experience

Training of Mark Breidenbach

Yale University Graduate Degree
Cornell University Undergraduate Degree
Stanford University Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Mark Breidenbach's experience

Connections

99

1st degree connections

8

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies4

Finance

Health Technology

Finance

Finance

See company connections
  1. Stock Market
  2. Insiders
  3. Mark Breidenbach
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW